DXCM

Latest market price

71.54

+1.06+1.50%

Overview Short InterestFilings

DXCMQT51DexCom, Inc.·NASDAQ

Overview Short InterestFilings

71.54+1.50%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RMD+1.76%$195.27 ZBH+1.90%$91.35 EW-1.42%$82.63 SNN+2.69%$30.57 PEN+0.26%$318.73 ALGN-0.73%$167.02 BSX+1.54%$44.25 PODD+3.08%$163.26

Snapshot

Index	S&P 500, NDX	P/E	29.81	EPS (ttm)	2.40	Insider Own	0.82%	Shs Outstand	385.87M	Perf Week	-6.67%

Market Cap	27.61B	Forward P/E	23.15	EPS next Y	3.09	Insider Trans	-3.33%	Shs Float	384.56M	Perf Month	2.57%

Enterprise Value	27.87B	PEG	0.40	EPS next Q	-	Inst Own	94.03%	Short Float	4.85%	Perf Quarter	14.10%

Income	933.06M	P/S	5.73	EPS this Y	10.83%	Inst Trans	-	Short Ratio	3.26	Perf Half Y	-3.22%

Sales	4.82B	P/B	9.32	EPS next Y	19.14%	ROA	14.03%	Short Interest	18.65M	Perf YTD	7.79%

Book/sh	-	P/C	15.46	EPS next 5Y	17.74%	ROE	33.83%	52W High	89.98 -20.49%	Perf Year	-17.23%

Cash/sh	-	P/FCF	19.31	EPS past 3/5Y	37.73% 10.48%	ROIC	18.03%	52W Low	54.11 32.21%	Perf 3Y	-46.46%

Dividend Est.	-	EV/EBITDA	18.88	Sales past 3/5Y	17.01% 19.33%	Gross Margin	61.84%	Volatility	3.26% 3.47%	Perf 5Y	-36.22%

Dividend TTM	-	EV/Sales	5.79	EPS Y/Y TTM	64.79%	Oper. Margin	21.45%	ATR (14)	2.69	Perf 10Y	266.31%

Dividend Ex-Date	-	Quick Ratio	1.64	Sales Y/Y TTM	19.46%	Profit Margin	19.31%	RSI (14)	47.35	Recom	2.21

Dividend Gr. 3/5Y	-	Current Ratio	1.95	EPS Q/Q	75.00%	SMA20	-1.82%	Beta	1.39	Target Price	84.09

Payout	0.00%	Debt/Eq	0.47	Sales Q/Q	15.06%	SMA50	-0.23%	Rel Volume	0.49	Prev Close	70.48

Employees	11,100	LT Debt/Eq	0.50	Earnings	Jul 30	SMA200	5.98%	Avg Volume	5.65M	Price	71.54

IPO Date	Apr 14, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.27% 1.47%	Net Debt/EBITDA	0.18	Volume	2,782,849	Change	1.50%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-16-26	Reiterated	Truist Securities	Buy	$94 → $87
Jun-23-26	Reiterated	Deutsche Bank	Buy	$86
Jun-15-26	Reiterated	Piper Sandler	Overweight	$75 → $88
Jun-10-26	Reiterated	UBS	Buy	$95
Jun-09-26	Reiterated	Mizuho	Outperform	$75 → $85
Jun-08-26	Reiterated	Raymond James	Strong Buy	$81 → $91
Jun-05-26	Reiterated	Stifel Nicolaus	Buy	$85 → $90
May-18-26	Reiterated	Barclays	Underweight	$67 → $64
May-18-26	Reiterated	Canaccord Genuity	Buy	$100 → $82
May-01-26	Reiterated	Bernstein	Outperform	$83 → $77

Company

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Ownership

Total institutional ownership94.03%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	4,818	4,662	4,033	3,622	2,910	2,449	1,927	1,476	1,032
Cost of Goods Sold Incl. D&A	1,839	1,864	1,595	1,333	1,027	768	647	545	368
Gross Profit	2,979	2,798	2,438	2,289	1,883	1,681	1,280	932	664
Selling, General and Administrative Excl. Other	1,331	1,291	1,286	1,185	1,008	811	621	516	433
Research and Development	599	595	552	506	484	604	360	274	417
Other Operating Expense	16	0	0	0	0	0	0	-1	0
Operating Income	1,034	912	600	598	391	266	300	142	-186
Interest Expense	17	18	19	20	19	19	85	60	23
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	187	195	128	133	18	10	10	22	83
Net Income Before Taxes	1,204	1,088	709	710	391	257	225	104	-126
Income Taxes	273	252	133	169	50	40	-269	3	1
Consolidated Net Income	931	836	576	542	341	217	494	101	-127
Net Income From Continuing Operations	931	836	576	542	341	217	494	101	-127
Net Income	931	836	576	542	341	217	494	101	-127
EPS (Recurring)	2.40	2.14	1.46	1.44	0.88	0.56	1.31	0.28	-0.36
EPS (Basic, Before Extraordinaries)	2.40	2.14	1.46	1.44	0.88	0.56	1.31	0.28	-0.36
EPS (Diluted)	2.34	2.09	1.42	1.30	0.80	0.51	1.27	0.27	-0.36
EBITDA	1,477	1,359	946	917	565	378	377	213	-75
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	30.57	31.76	54.77	95.45	141.55	263.22	72.78	202.56	—
Price To Sales Ratio	5.72	5.55	7.81	13.22	15.14	21.21	18.13	13.49	10.24
Gross Margin	61.83	60.02	60.45	63.20	64.71	68.64	66.42	63.14	64.34
Operating Margin	21.46	19.56	14.88	16.51	13.44	10.86	15.57	9.62	-18.02
Net Margin	19.32	17.93	14.28	14.96	11.72	8.86	25.64	6.84	-12.31
Shares Outstanding	385	390	405	386	389	387	378	364	353
Market Capitalization	27,543	25,884	31,497	47,899	44,050	51,951	34,939	19,907	10,572
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAYER KEVIN R	Executive Chair	Jul 20 '26	Sale	76.32	26,756	2,041,999	328,970	Jul 21
Brown Michael Jon	EVP Chief Legal Compliance Off	Jul 15 '26	Sale	74.42	1,700	126,514	104,653	Jul 16
SAYER KEVIN R	Executive Chair	Jul 06 '26	Sale	72.00	26,756	1,926,432	355,726	Jul 07
FOLETTA MARK G	Director	Jun 15 '26	Sale	74.13	4,000	296,540	52,852	Jun 17
Brown Michael Jon	EVP Chief Legal Compliance Off	Jun 15 '26	Sale	75.55	1,700	128,435	106,353	Jun 17
Coleman Jon	EVP, Chief Commercial Officer	Jun 04 '26	Sale	74.13	4,911	364,052	95,450	Jun 05
Coleman Jon	EVP, Chief Commercial Officer	Jun 03 '26	Sale	73.00	4,912	358,576	100,361	Jun 05
SAYER KEVIN R	Executive Chair	May 21 '26	Sale	72.00	26,759	1,926,648	382,482	May 26
Brown Michael Jon	EVP, Chief Legal Officer	May 15 '26	Sale	59.91	1,700	101,847	109,504	May 19
Heller Bridgette P	Director	May 12 '26	Sale	60.01	1,012	60,730	25,007	May 14
Brown Michael Jon	EVP, Chief Legal Officer	Apr 15 '26	Sale	63.04	1,700	107,168	111,204	Apr 16
Brown Michael Jon	EVP, Chief Legal Officer	Mar 16 '26	Sale	64.85	1,700	110,245	112,904	Mar 18
Heller Bridgette P	Director	Feb 12 '26	Sale	68.01	1,012	68,826	26,019	Feb 17
Collins Richard Alexander	Director	Nov 14 '25	Sale	59.05	2,906	171,599	35,088	Nov 17
Heller Bridgette P	Director	Nov 12 '25	Sale	58.07	1,012	58,767	27,031	Nov 12